Is France falling behind in the deployment of its digital medical devices compared to its neighbors?
As of mid-February 2023, of the 42 DIGAs listed, 16 DIGAs have been admitted and can be consulted by patients. A classification by pathological group or brand name of the devices included in this program is emerging. A pricing model which is structured with prices varying from €119 to €952 per quarter and the submission of manufacturers to a fixed maximum amount varying according to the pathology group to which the device belongs, the DIGA status (permanently admitted or trial) and the number of activation codes delivered.
STATUT DU DIGA : Admission à l’essai
STATUT DU DIGA : Admission permanentes
2 000 codes
80% du montant max
Montant max (pas appliqué la première année d’inclusion)
10 000 codes
60% du montant max
75% du montant max
A system very favorable to digital DMs:
- With patients better monitored and actors in their health (a very accessible system);
- An adaptation of the system to the solutions presented;
- Stable and fairly high redemption prices with low degressivity.
A few points to consolidate:
- 26 DIGAs with no evidence of efficacy after one year are still in the trial period with temporary coverage;
- An increase in the average prices for the DIGAs under test is observed, whereas the "permanent" DiGAs have a constant or slightly decreasing price.
Wouldn't it be time for France to rely more on this success to consolidate the launch of PECAN to finally enter the digital health race?